Animal Model Market (2025 - 2033) Size, Share & Trends Analysis Report By Animal Type (Mice, Guinea Pigs), By Application (Cancer, Infectious Disease), By End Use, By Region, And Segment Forecasts

Animal Model Market Summary

The global animal model market size was estimated at USD 2.42 billion in 2024 and is projected to reach USD 5.18 billion by 2033, growing at a CAGR of 8.94% from 2025 to 2033. The increasing use of animal models in biomedical, neurological, genetic, toxicology, and cancer research is driving global market growth.

Moreover, growing R&D efforts by biopharmaceutical companies to develop novel therapeutics and the emergence of advanced technologies, such as CRISPR, in biomedical research, are other factors contributing to industry expansion.

Increasing Prevalence of Chronic and Lifestyle Diseases

The market for animal models is significantly influenced by the rising incidence of lifestyle and chronic diseases worldwide. Aging populations, urbanization, and unhealthy lifestyle choices are contributing to a steady increase in conditions like cancer, diabetes, cardiovascular disorders, and neurological diseases. Extensive preclinical research is necessary to understand the pathophysiology, course, and response to potential treatments of these complex diseases. Researchers can study disease mechanisms and assess new drug candidates in a controlled setting using animal models, which helps create more specialized and efficient treatment options.

Furthermore, the need for personalized medicine and novel therapies, which mainly rely on preclinical testing using animal models, has increased due to the rising burden of chronic diseases. To achieve higher success rates in drug development, pharmaceutical and biotechnology companies are increasingly investing in animal studies to confirm the therapeutic efficacy and safety of their products before clinical trials.

Preclinical Research Needs

One of the primary factors driving the animal model industry is the growing importance of preclinical research in the biotechnology and pharmaceutical sectors. Animal models are essential Early in the drug discovery and development because they enable researchers to assess the pharmacological characteristics, safety, and effectiveness of novel therapeutic candidates before human trials. They aid in simulating human disease conditions, allowing researchers to examine drug responses and biological mechanisms in a controlled environment. To mitigate risks and enhance translational accuracy, it is now more crucial than ever to have accurate and predictive animal models, given the increasing complexity of contemporary treatments, particularly in biologics, vaccines, and gene therapies.

By enhancing the accuracy of preclinical testing, these models enable researchers to generate reliable and reproducible data essential for regulatory approvals. The growing emphasis on personalized medicine and rare disease research further increases the need for humanized and customized animal models that can replicate particular genetic or metabolic traits. Using animal models for preclinical validation remains a major driver of market expansion worldwide, as pharmaceutical and biotechnology companies continue to expand their R&D pipelines.

Market Concentration & Characteristics

Rapid developments in genetic engineering, molecular biology, and bioinformatics have led to a high level of innovation in the animal model industry. Replicating complex human diseases with greater accuracy and predictability has become possible with the creation of transgenic, humanized, and CRISPR/Cas9 gene-edited models. These developments lessen the translational gaps between preclinical and clinical research by enabling more precise studies of disease mechanisms, immunological responses, and therapeutic effects. The market's robust innovation trajectory and vital role in advancing contemporary drug discovery and biomedical research are highlighted by this ongoing technological evolution.

The animal models industry has experienced a moderate to high level of mergers and acquisitions (M&A) activity in recent years, reflecting businesses' strategic intent to expand their product offerings, enhance their technological capabilities, and strengthen their global presence. Major players purchase smaller, specialized companies that specialize in humanized, genetically modified, or disease-specific models to boost innovation and gain a competitive advantage. These mergers enable businesses to achieve operational efficiencies and better meet evolving research needs in drug discovery and biomedical studies, while also facilitating market expansion and diversification.

Regulations play a crucial role in shaping the animal model industry, as strict guidelines govern the use of animals in research to ensure adherence to ethical standards, promote animal welfare, and maintain scientific validity. The stringent preclinical testing procedures required by organizations such as the FDA, EMA, and regional animal ethics committees directly impact the need for validated and approved animal models.

Product expansion is a key driver in the animal model industry, as companies continually develop new and specialized models to meet the evolving needs of pharmaceutical, biotechnology, and academic research. Disease-specific, transgenic, humanized, and genetically modified models have been introduced to replicate complex human conditions more accurately. Offering various rodent, non-rodent, and alternative species models, as well as related research services and consumables, is another way to broaden product portfolios and enable providers to offer complete preclinical solutions.

Regional expansion has become a vital growth strategy in the animal model industry, as key players aim to strengthen their presence across emerging and established research hubs. Businesses are increasingly investing in Asia-Pacific countries, such as China, India, and South Korea, where growing R&D expenditures, the development of biotechnology industries, and supportive government policies drive high demand for preclinical research models. Similarly, expansion into North America and Europe is ongoing due to their sophisticated research infrastructure, dense pharmaceutical industries, and strict regulatory frameworks that require a significant amount of preclinical testing.

Animal Type Insights

The mice segment accounted for the largest revenue share of 53.95% in 2024 and is expected to witness the fastest growth rate from 2025 to 2033. Factors such as increasing investments and technological advancements in mouse model technology are anticipated to drive segment growth. In addition, rising implications of mouse clinical trials for more predictive outcomes and propelling demand for personalized medicine are further contributing to the demand for mice models. For instance, in March 2023, researchers from the National Institutes of Health studied an enhanced genetic animal model of Down syndrome. The novel mouse model delivered potential therapeutic options for managing the condition. 

The rat segment is a fast-growing part of the market. It is driven by its ease of handling, physiological similarity to humans, and increasing use in disease modeling, toxicology studies, and research involving genetically modified organisms.

Application Insights

The cancer segment dominated the application segment in 2024, with a market share of 46.75%, and is expected to register the fastest growth rate over the forecast period. This is due to the exponential increase in the use of animal models in drug screening and preclinical testing to evaluate the efficacy and safety of anti-cancer therapeutics. Moreover, animal models enable researchers to assess the therapeutic index, bioavailability, and pharmacokinetic properties of anticancer therapeutics before transitioning to human clinical trials.

The immunological disease segment is expected to grow significantly during the forecast period, driven by the rising prevalence of autoimmune and inflammatory disorders, as well as the increasing demand for preclinical models to develop targeted therapies and vaccines.

End Use Insights

The pharmaceutical & biotechnology companies segment captured the largest market share of 39.00% in 2024. Increasing efforts by companies to develop novel treatment regimens are projected to drive the segment’s growth. In addition, many research-driven pharmaceutical companies and various initiatives they undertake are projected to fuel segment growth.

The contract research organization (CRO) segment is expected to register the fastest CAGR during the forecast period, driven by the outsourcing of preclinical research, rising demand for specialized animal models, and the need for cost-effective, efficient drug development solutions.

Regional Insights

North America dominated the global market with a 48.19% share in 2024, and the region is expected to continue registering a steady growth rate during the forecast period. The region’s growth is attributed to the presence of key players and their various strategic initiatives. In addition, the growing field of biomedical research and increasing investment in clinical trials are contributing to regional market growth. Furthermore, advancements in genetic engineering and the increasing adoption of animal-based models for studying drug profiling and characterization will likely open up new avenues for market growth.

U.S Animal Model Market Trends

The animal model market in the U.S. is growing due to high R&D expenditure in the pharmaceutical and biotechnology sectors, the presence of leading research institutions, and stringent regulatory requirements that drive extensive preclinical testing. Regional market demand is also increasing due to a growing emphasis on genetically modified models, novel treatments, and research on chronic illnesses.

Europe Animal Model Market Trends

The animal model market in Europe is driven by well-established pharmaceutical and biotechnology sectors, strong government support for biomedical research, and stringent regulatory standards that require comprehensive preclinical testing. The primary market drivers are the well-established biotechnology and pharmaceutical industries, robust government support for biomedical research, and stringent regulations that require extensive preclinical testing.

The UK animal model market is expanding steadily, driven by its strong biomedical research ecosystem, growing pharmaceutical and biotechnology sectors, and supportive government initiatives. Increased adoption of humanized, transgenic, and disease-specific models for preclinical studies further strengthens the country’s position as a key hub for European animal-based research.

The animal model market in Germany leads the European market owing to its advanced research infrastructure, significant R&D investment, and well-established biotech and pharmaceutical industries. The nation's dedication to cutting-edge preclinical models, such as transgenic and disease-specific animals, improves the effectiveness of drug development and solidifies its position as the market leader in the region.

Asia Pacific Animal Model Market Trends

The animal model market in the Asia Pacific is expected to register the fastest CAGR of 10.1% from 2025 to 2033. The high disease burden of chronic diseases, such as cancer, immunological disorders, and rare genetic disorders, is projected to support the growth of the regional market.

China animal model market is experiencing rapid growth, driven by increased investment in pharmaceutical and biotech research and development, the growing demand for preclinical testing, and supportive government policies. The emphasis on genetically engineered, transgenic, and disease-specific models to support drug discovery and translational research is also driving market growth across the region.

The animal model market in Japanis supported by advanced pharmaceutical research and government backing for biomedical innovation. Market growth is catalyzed by the increasing use of genetically modified and disease-specific models to design more efficacious and targeted therapies, thereby influencing translational research outcomes.

MEA Animal Model Market Trends

The animal model market in the Middle East and Africa is experiencing stable growth, driven by rising investment in pharmaceutical R&D, the expansion of biotechnology research centers, and increasing demand for preclinical services. Furthermore, increased awareness of advanced disease models and genetically modified species contributes to the adoption of animal models in the Middle East and Africa.

Kuwait animal model market is experiencing growth, driven by the expansion of research in healthcare and life sciences, as well as increased government funding for biomedical research and development, along with enhanced collaborations with international research organizations.

Key Animal Model Company Insights

The market is characterized by several established players who dominate through comprehensive product portfolios, advanced technological capabilities, and strategic collaborations. Leading companies, such as Charles River Laboratories, The Jackson Laboratory, genOway, Taconic Biosciences, Inc., and Janvier Labs, have maintained a significant market share thanks to their high-quality animal models, broad disease coverage, and global distribution networks.

Crown Bioscience, Inotiv, and BIOCYTOGEN are expanding their reach by offering tailored solutions that include transgenic, humanized, and disease models, alongside preclinical delivery services that cater to the growing needs of pharmaceutical companies, biotechnology companies, and academic research institutions.

Existing players and emerging disruptors create a dynamic market landscape. Mergers and acquisitions, partnerships, changes in genetic engineering, the emergence of transgenic models, and an abundance of in vivo research capabilities are all contributing to increasing competition. Companies that combine new science with custom preclinical solutions can create lasting value in this rapidly changing environment.

Recent Developments

• In August 2025, Taconic Biosciences and Cyagen partnered in North America and Europe to provide streamlined access to over 16,000 genetically engineered mouse and rat models, enhancing preclinical research efficiency.

• In November 2022, Avista Capital Partners acquired Taconic Biosciences in the U.S., aiming to leverage its healthcare expertise to support Taconic’s growth in genetically engineered rodent models (GEMs) and related preclinical services.

Animal Model Market Report Scope

Global Animal Model Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global animal model market based on animal type, application, end use, and region:

• Animal Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Mice

  • Rat

  • Guinea Pigs

  • Rabbits

  • Hamsters

  • Others

• Application Outlook (Revenue, USD Million, 2021 - 2033)

  • Cancer

  • Immunological Disease

  • Infectious Disease

  • Others

• End Use Outlook (Revenue, USD Million, 2021 - 2033)

  • Pharmaceutical & Biotechnology Companies

  • Academic Research Institute

  • Contract Research Organization

• Regional Outlook (Revenue, USD Million, 2021- 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • South Korea

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait